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Background: The purpose of the study was to evaluate the impact of 2-[fluorine-18]fluoro-2-deoxy-D-glucose–
positron emission tomography (FDG–PET)/computed tomography (CT) during follow-up of patients with Hodgkin’s
lymphoma.
Patients and methods: Patients in complete remission or an unconfirmed complete remission after first-line therapy
who received FDG–PET/CT during their follow-up were analyzed retrospectively. Confirmatory biopsy was mandatory
in case of recurrence.
Results: Overall, 134 patients were analyzed. Forty-two (31.3%) patients had a recurrence. The positive predictive
value of FDG–PET/CT was 0.98. Single-factor analysis identified morphological residual mass [P = 0.0005, hazard
ratio (HR) 3.4, 95% confidence interval (CI) 1.7–6.6] and symptoms (P < 0.0001, HR 4.9, 95% CI 2.4–9.9) as significant
risk factors for relapse. By multivariate analysis, morphological residual mass was the only significant risk factor for
early follow-up (<24 months) (P = 0.0019, HR 7.6, 95% CI 2.1–27.3). Advanced stage (P = 0.0426, HR 3.6, 95% CI
1.1–12.3) and the presence of symptoms (P = 0.0009, HR = 14.6, 95% CI 3.0–69.7) were found to be significant risk
factors for later follow-up (>24 months).
Conclusions: Asymptomatic patients without morphological residues and an early stage of disease do not need
a routine FDG–PET/CT for follow-up. Asymptomatic patients with morphological residues should receive routine
follow-up FDG–PET/CT for the first 24 months. Only patients with advanced initial stage do need a routine follow-up
FDG–PET/CT beyond 24 months.
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introduction
The primary goal of follow-up in cancer patients is to identify
early recurrent disease. In Hodgkin’s lymphoma (HL),
detection of early or even preclinical relapse would allow the
timely administration of appropriate salvage therapy and
eventually improve survival [1, 2]. Current guidelines for
patients with HL recommend computed tomography (CT) to
assess the remission status after first-line treatment and the only
indication for additional radiographic investigations is the new
onset of suspicious clinical symptoms [3]. 2-[Fluorine-
18]fluoro-2-deoxy-D-glucose–positron emission tomography
(PET) may be considered for pretreatment staging and for the
evaluation of response during and after first-line treatment [4].
Only limited evidence exists to support the use of FDG–PET
for routine follow-up of asymptomatic patients [5, 6]. One
recent study evaluated serial FDG–PET for follow-up of HL
and aggressive non-Hodgkin’s lymphoma (NHL) patients
prospectively [7]. A substantial subset of patients had
recurrence of HL and NHL during follow-up, and the authors
concluded that FDG–PET might be a valid tool for surveillance
of these patients.
Several risk factors for relapse of HL after successful first-line
treatment have been described in the last decade [8]. The goal
of our study was to investigate the value of follow-up FDG–
PET/CT in patients with HL after completion of first-line
therapy and emphasize the impact of risk factors on the
recurrence rates. We aimed to identify patients at risk for
relapse and to define a subset of patients who would benefit
from FDG–PET/CT imaging during follow-up.
patients and methods
patients
Patients with HL in complete remission after first-line treatment who
received at least one FDG–PET/CT during their follow-up from the
beginning of 2002 until the end of 2008 were included in this study.
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FDG–PET/CT imaging data were acquired on a combined PET/CT in-line
system (Discovery LS, RX or Discovery STE, GE Health Systems,
Milwaukee, WI), which permits the acquisition of coregistered CT and PET
images in a single session.
All FDG–PET/CT scans were evaluated for the presence of abnormal
FDG uptake and residual disease. All image analysis was routinely carried
out by two dual-board-certified nuclear radiology physicians in consensus.
Complete remission in these patients had to be documented by one
appropriate imaging modality within 1 month after completion of first-line
treatment (CT alone, CT and FDG–PET, or FDG–PET/CT). All imaging
was carried out at our institution. CT scans were assessed for residual
disease using the International Workshop Criteria (IWC) [9].
A residual morphological mass after the end of treatment was defined as
a lesion that had regressed by >75% but was still >1.5 cm in its greatest axial
diameter. We further documented the initial stage of disease using the Ann
Arbor classification. Age, gender and signs of recurrence were assessed
and recorded by the referring physician before the follow-up FDG–PET/CT
imaging was carried out. Signs of recurrence included B symptoms or new
suspicious masses. Relapse-free survival (RFS) was assessed in all patients
from the initial date of diagnosis until the date of recurrence as
documented by FDG–PET/CT. Histological confirmation was mandatory in
all patients with suspected recurrent disease found with FDG–PET/CT. Our
institutional ethics committee had approved the study. Due to the
retrospective nature of the study, written informed consent of the patients
was waived.
assessment of risk factors and patient classification
CT scans after completion of first-line treatment were assessed for residual
morphological masses at the initial lymphoma sites using the IWC criteria
described above. Patients were assessed for advanced (IIIA–IVB) versus
early (IA–IIB) stage by Ann Arbor classification, age (>45 and <45 years)
and gender. Patient classification into the symptomatic or asymptomatic
group was done on the basis of reported symptoms or referral notes by the
treating physician.
statistical analysis
Three groups of patients were analyzed: asymptomatic patients before referral
for FDG–PET/CT, symptomatic patients before referral for FDG–PET/CT
and all the patients combined. All three groups were analyzed according to
the known risk factors such as a residual morphological mass after the end of
treatment, advanced stage (greater than IIB), age >45 years and male gender.
Log-rank tests and Kaplan–Meier analysis were used to assess the influence of
single risk factors. Cox regression was used to assess partial influences of
several risk factors. All statistical calculations were carried out with the
Statistical Analysis Software SPSS 16 (SPSS Inc., Chicago, IL).
results
patients and disease status
We collected data from patients with HL who received one or
more follow-up FDG–PET/CT scans from 2002 to 2008 at
our institution. From 206 patients initially indexed, 72 patients
had to be excluded from analysis due to incomplete follow-up
data or administration of second-line treatment before
FDG–PET/CT was carried out. Overall, 134 patients with HL
(81 male, 53 female; mean age 34.12 6 15.34 years) were
eligible for analysis. All patients had initially received CT alone
(n = 33), FDG–PET and CT (n = 16), or FDG–PET/CT
(n = 85) at the end of their first-line therapy. The patient
populations are listed in Table 1.
Eighty-three (61.9%) patients had no symptoms and 51
(38.1%) patients were symptomatic before FDG–PET/CT.
Forty-two (31.3%) patients had a recurrence during further
follow-up. Disease recurrence was confirmed by histology and
all relapsing patients received salvage chemotherapy. Ten
(7.5%) patients in the asymptomatic patient group and 32
(23.9%) in the symptomatic patient group had recurrence
as determined by FDG–PET/CT. The mean RFS in the
patient group with recurrence (n = 42) was 26.9 months
(4.6–191.5 months). The mean follow-up time of patients
without recurrence from the end of first-line treatment until
last negative FDG–PET/CT scan (n = 92) was 38.72 months
(4.8–203 months). None of the patients with a negative
follow-up FDG–PET/CT scan relapsed before the end of the
study. FDG–PET/CT was able to detect relapses with a positive
predictive value (PPV) of 0.98.
risk factor assessment
single risk factors. In the whole patient population (n = 134),
symptoms before follow-up FDG–PET/CT and morphological
residual masses seen on CT after the end of treatment were
predictive for recurrence (P < 0.0001, hazard ratio (HR) 4.886,
Table 1. Asymptomatic and symptomatic patient groups
n %
A. Asymptomatic patients (n = 83)
Recurrence
Yes 10 12.0
No 73 88.0
Morphological residual mass
Yes 41 49.4
No 42 50.6
Stage of disease
Early (IA–IIB) 51 61.4
Advanced (IIIA–IVB) 32 38.6
Gender
Female 36 43.4
Male 47 56.6
Advanced age
<45 years 64 77.1
>45 years 19 22.9
B. Symptomatic patients (n = 51)
Recurrence
Yes 32 62.7
No 19 37.3
Morphological residual mass
Yes 25 49.0
No 26 51.0
Stage of disease
Early (IA–IIB) 29 56.9
Advanced (IIIA–IVB) 22 43.1
Gender
Female 17 33.3
Male 34 66.7
Advanced age
<45 years 42 82.4
>45 years 9 17.6
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95% confidence interval (CI) 2.403–9.938 and P = 0.0005, HR
3.362, 95% CI 1.710–6.609; Figure 1A and B). Age >45 years
at initial diagnosis, advanced stage of disease and male gender
were not associated with a higher risk of relapse.
When analyzing the groups of symptomatic and
asymptomatic patients separately, a documented
morphological residual mass after first-line treatment remained
the only significant risk factor for relapse [asymptomatic:
P = 0.0011 (HR = 9.033, 95% CI 2.418–336.700); symptomatic:
P = 0.01802 (HR = 2.4068, 95% CI 1.1667–4.9647)].
multiple risk factors. Cox regression was used to assess the
association between several risk factors and hazard of
recurrence. Analyzed covariates were age >45 years at time of
diagnosis, a morphological residual mass, gender, advanced
stage of disease and symptoms before referral for FDG–PET/
CT. The overall model fit shows a significant chi square 42.067,
5 df, P < 0.0001. Significant covariates were morphological
residual mass (P = 0.00016, HR = 3.8387, 95% CI 1.9158–
7.6915), advanced stage (P = 0.03644, HR 1.9900, 95% CI
1.0478–3.7794) and symptoms before referral (P < 0.0001, HR
5.1161, 95% CI 2.5002–10.4688) (Table 2).
These risk factors were added (zero to three risk factors) and
used in the Kaplan–Meier method and the log-rank test.
Symptoms, a morphological residual mass, advanced stage of
disease or a combination of these factors identified patients at
risk for recurrence (P < 0.0001). No asymptomatic patient
without a morphological residual mass and an early stage of
disease showed recurrence on the FDG–PET/CT and none of
them recurred during later follow-up. The median RFS was not
reached in patients without any of these risk factors. In patients
with one risk factor present the RFS was 153.4 months, with
two risk factors 35.2 months and with three risk factors
16.2 months (Figure 2). We also used the Cox proportional
hazards regression within the first 24 months (patients n = 69)
and after 24 months (patients n = 65). In the first 24 months,
the only significant risk factor was morphological residual mass
(P = 0.0019, HR 7.5994, 95% CI 2.1170–27.2796). Risk factors
for recurrence after 24 months were symptoms (P = 0.0009,
HR = 14.5627, 95% CI 3.0398–69.7657) and advanced
stage (P = 0.0426, HR 3.6144, 95% CI 1.0569–12.3601)
(Tables 3 and 4).
discussion
We evaluated the role of FDG–PET/CT for patients with HL
after first-line therapy. Our study population included
symptomatic as well as asymptomatic patients after first-line
therapy. All patients were analyzed with regard to the
Figure 1. (A) Kaplan–Meier analysis of the relapse-free survival of
asymptomatic patients compared with symptomatic patients during
follow-up; P < 0.0001, HR 4.886, 95% confidence interval (CI) 2.403–9.938
(solid line: asymptomatic patients and dashed line: symptomatic patients).
(B) Kaplan–Meier analysis of the relapse-free survival of patients with and
without morphological residual mass after end of first-line treatment; P =
0.0005, HR 3.362, 95% CI 1.710–6.609 (solid line: patients with no
morphological residual mass and dashed line: patients with morphological
residual mass).
Table 2. .Cox proportional hazards regression with risk factors as
covariates in all patients (overall model fit chi square 42.067, 5 df,
significance level P < 0.0001)
Factor Significance
(P value)
Hazard
ratio
95% CI of
hazard ratio
Age > 45 0.4463 0.7241 0.3168–1.6550
Stage > IIB 0.0364 1.9900 1.0478–3.7794
Male gender 0.8551 0.9414 0.4941–1.7938
Residual disease 0.0002 3.8387 1.9158–7.6915
Symptoms <0.0001 5.1161 2.5002–10.4688
Advanced stages, residual disease and symptoms are predictive factors for
recurrence in the follow-up of HL patients in FDG–PET/CT.
CI, confidence interval; HL, Hodgkin’s lymphoma; FDG–PET, 2-[fluorine-
18]fluoro-2-deoxy-D-glucose–positron emission tomography; CT,
computed tomography.
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established risk factors: advanced stage of disease, advanced age,
gender and morphological residual mass after first-line
treatment.
Symptoms as the reason for patient referral were the most
important risk factor. However, a few asymptomatic patients
also had unsuspected recurrence. Further prognostic risk
factors were tumor residues at the end of treatment and
advanced stage of disease. None of the patients with initial
early-stage disease and without a residual mass relapsed during
follow-up. In our study, the high diagnostic yield of FDG–PET/
CT for the follow-up is evident by the PPV of 0.98.
In a recent study by Zinzani et al., a large prospective trial
with 421 patients, FDG–PET found 41 relapses at 6 months, 30
relapses at 12 months, 26 relapses at 18 months and 10 relapses
at 24 months. This study concludes that FDG–PET is a valid
tool for follow-up of patients with HL and NHL [7]. However,
this conclusion is debatable because of rising concerns over
the limitless use of imaging modalities regarding patient safety
and economic costs [10]. Using the patient population of the
latter study, 842 scans were done after 1 year identifying 71
relapses. Therefore, 11.86 scans were needed to identify one
relapse. Using the full 2-year period, a total of 1684 FDG–PET
scans identified 107 relapses. This equals 15.73 FDG–PET scans
to identify one relapse of HL or NHL. Several studies have
shown that diagnosis of recurrence is made on clinical grounds
in 80% of all cases; it is the patient or the physician who
indicates the possibility of relapse on clinical grounds, before
confirmation by routine imaging studies [11–13].
We observed 10 (12%) recurrences in the asymptomatic
patient group (n = 83), corresponding to 8.3 scans for detection
of one relapse in asymptomatic patients. This result is similar
to the data presented by Zinzani et al. In the symptomatic
patient population (n = 51), we observed 32 (63%) recurrences.
Accordingly, 1.59 scans were necessary to find one true
recurrence in patients with new suspicious symptoms.
By combining the three parameters morphological residual
mass after first-line treatment, symptoms and advanced stage of
disease to create a risk score, we can assess the risk of relapse
for a patient and the benefit of further imaging. While we
observed no recurrences in patients without any of the three
parameters, the RFS decreased markedly in patients who had
a higher risk score. By using such risk-adapted strategy for
the follow-up of patients with HL, the need for FDG–PET/CT
scanning could be optimized and lead to reduced
radiation exposure for our patients and savings of health care
costs.
We also found a time delay of the risk factor ‘symptoms
before referral’ in the prediction of recurrence. Cox
proportional hazards regression in the first 24 months
identified only morphological residual mass to be predictive for
recurrence. After 24 months, symptoms before referral and
advanced stage of disease were predictive for recurrence but
residual morphological masses were not predictive. This finding
highlights the importance of morphological residual mass as
a risk factor in early follow-up, as demonstrated by a recent
prospective trial [14]. Accordingly, surveillance of
asymptomatic patients with FDG–PET/CT may be useful
during early follow-up, while the probability of a relapse
decreases after the first 24 months. On the other hand,
Table 3. Cox proportional hazards regression with risk factors as
covariates in all patients within the first 24 months (overall model fit chi
square 18.230, 5 df, significance level P = 0.0027)
Factor Significance
(P value)
Hazard
ratio
95% CI of
hazard ratio
Age > 45 0.5553 0.7027 0.2189–2.2556
Stage > IIB 0.5225 1.3443 0.5453–3.3140
Male gender 0.7825 0.8872 0.3810–2.0659
Residual disease 0.0019 7.5994 2.1170–27.2796
Symptoms 0.0925 2.1438 0.8859–5.1881
Residual disease and symptoms are predictive factors for recurrence in the
early follow-up (<24 months) of HL patients in FDG–PET/CT.
CI, confidence interval; HL, Hodgkin’s lymphoma; FDG–PET, 2-[fluorine-
18]fluoro-2-deoxy-D-glucose–positron emission tomography; CT,
computed tomography.
Table 4. Cox proportional hazards regression with risk factors as
covariates in all patients after the first 24 months (overall model fit chi
square 21.53, 5 df, significance level P = 0.0006)
Factor Significance
(P value)
Hazard
ratio
95% CI of
hazard ratio
Age > 45 0.4831 0.6272 0.1714–2.2947
Stage > IIB 0.0416 3.6144 1.0569–12.3601
Male gender 0.6469 0.7782 0.2676–2.2633
Residual disease 0.1998 2.1595 0.6696–6.9648
Symptoms 0.0009 14.5627 3.0398–69.7657
Only symptoms are predictive for recurrence in the later follow-up (>24
months) of HL patients in FDG–PET/CT.
CI, confidence interval; HL, Hodgkin’s lymphoma; FDG–PET, 2-[fluorine-
18]fluoro-2-deoxy-D-glucose–positron emission tomography; CT,
computed tomography.
Figure 2. Kaplan–Meier analysis of the relapse-free survival of patients
with the risk factors symptoms, morphological residual mass and advanced
stage (solid line: zero risk factors, dashed line: one risk factor, points: two
risk factors and dashed line and points: three risk factors), P < 0.0001.
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symptoms may be important during later follow-up and
FDG–PET/CT should be considered in symptomatic patients.
The retrospective nature of this study is its most important
limitation. It does not allow us to draw definitive conclusions.
Furthermore, not all patients had FDG–PET at the end of first-
line treatment. The Revised Response Criteria for Malignant
Lymphoma published in Journal of Clinical Oncology 2007
includes FDG–PET at the end of first-line therapy [9]. Current
oncology guidelines do not include mandatory FDG–PET after
the end of therapy and our patient data reflect a normal HL
patient collective. The RFS for our collective patient data is low
compared with the data usually reported in the literature. This
reflects a patient referral for PET/CT due to suspected
recurrence by the treating physician and reflects a bias.
However, the goal of our study was to develop a rationale and
cost-effective strategy for the use of FDG–PET/CT imaging in
a well-defined patient population after completion of first-line
therapy.
In conclusion, FDG–PET/CT reliably detects recurrent HL
after first-line therapy. However, it should only be considered
in patients with clinical signs of recurrence at any time point,
in patients with morphological residual mass within the first
24 months and in patients with advanced initial stage (greater
than IIB) after 24 months after end of first-line treatment.
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